Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Tramway Venture Partners is a venture capital firm founded in New Mexico, focusing on life science companies. They have a portfolio of 7 companies and typically invest in the first institutional round after incubators and angel investors. Their investment strategy emphasizes the intersection of physical sciences, information technology, and healthcare.
Tramway Venture Partners invests in seed and early-stage life science companies, targeting opportunities that require less than $30 million to exit. They seek companies with strong management teams, significant intellectual property, and clear market strategies. Their check sizes can go up to $30 million.
Notable companies in Tramway Venture Partners' portfolio include BennuBio, a developer of a flow cytometry platform; Breezy Med, which created a biohazard disinfection platform; Circular Genomics, focused on personalized diagnostics for neurological disorders; Epistemix, known for predictive modeling; Nob Hill Therapeutics, innovating drug delivery technologies; Vitazi.ai, delivering an AI-powered diagnostic imaging platform; and WavDyn, specializing in visual performance measurement.
Submit through their form at https://tramwayventures.com/contact/.
Yes, Tramway typically leads the first institutional round of funding after incubators and angel investors.
Tramway focuses on seed and early-stage investments, but specific details on follow-on investments are not provided.
The firm targets companies that require less than $30 million to exit, but the size of their current fund is not disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.